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PMH42 HOSPITALIZATION AND EMERGENCY ROOM VISITS BEFORE AND AFTER TREATMENT WITH ATYPICAL ANTIPSYCHOTICS
AstraZeneca Pharmaceuticals LP, Wilmington, DE, USA; 2 HealthMetrics Outcomes Research, Groton, CT, USA OBJECTIVE: Examine the mean difference in hospitalization and emergency room (ER) visit rates pre and post-initiation on olanzapine, quetiapine or risperidone. METHODS: Retrospective analysis of a commercial claims database capturing inpatient, outpatient and prescription drug services. Individuals having a mental illness diagnosis, and initiated with olanzapine (N = 8730), quetiapine (N = 5709) or risperidone (N = 9339) between July 1, 1998 and July 2, 2002 were identified. Mean differences in the hospitalization or ER visit rates between the pre-and post-six month periods across the three-treatments were examined using ANCOVA, controlling for age, gender, region, and type of mental illness diagnosis. RESULTS: Individuals initiated with olanzapine or risperidone were found to have a significantly higher difference in the hospitalization (2.19%, p < 0.0001; 1.72%, p < 0.0001) or ER visit rates (3.80, p < 0.0001; 4.60%, p < 0.0001) post initiation of medication compared to the six months prior to initiation of medication. In contrast, individuals who were initiated with quetiapine had a significantly lower difference in the hospitalization (-4.37%, p < 0.0001) or ER visit rates (-2.89%, p < 0.0001) post-initiation of quetiapine compared to the six months prior-initiation of quetiapine. CONCLUSION: Quetiapine, unlike olanzapine or risperidone, may be associated with fewer hospitalizations and ER visits after medication initiation. These results may be suggestive of a more favorable side effect profile and/or better compliance with Quetiapine, and needs further investigation.
PMH43 IMPACT OF A PSYCHOEDUCATION PROGRAM ON HEALTH STATUS OF SEVERE AND PERSISTENTLY MENTALLY ILL
Bellnier T 1 , Pearce J 2 1 SUNY University at Buffalo, Buffalo, NY, USA; 2 GPI, Inc, Rochester, NY, USA OBJECTIVE: The severe and persistently mentally (SPMI) have greater rates of metabolic disorders than the general population (GP). Wellness programs have demonstrated a reduction in health care costs for the GP. A program designed to reduce the rate of metabolic disorders and their risk factors may prove to signifcantly reduce annual health care cost in the SPMI. The study goal was to evaluate the effect on metabolic syndrome risks of a psychoeducation program designed for SPMI. METHOD: Overweight patients were randomly selected for participation in the study. A psychoeducation program which included modules on nutrition and active exercise was developed and tested. The study had a acute(1 hr. 3 X week) phase for three-months and a maintenance phase (1 hr. 1 X month) for three-months. Vitals and lab tests were taken every
